RXRXHIGH SIGNALFINANCIAL10-K

RXRX shows massive 51% R&D spending increase driving net losses up 39% to $645M, despite strong revenue growth and improved cash position.

The dramatic R&D expense surge to $475M suggests aggressive investment in AI-driven drug discovery capabilities, which aligns with management's confident pivot from "vision and promise" to demonstrating "clinical reality." While concerning for near-term profitability, this could signal accelerated progress toward commercialization if the AI platform is delivering results.

Comparing 2026-02-25 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

RXRX presents a mixed but ultimately concerning financial picture with revenue growing a solid 27% to $75M while R&D expenses exploded 51% to $475M, driving net losses up 39% to $645M. The company strengthened its balance sheet with cash rising 25% to $743M and total debt falling 50% to $10M, while reducing current liabilities by 21%. This suggests RXRX is burning significant cash to accelerate AI drug discovery development, betting heavily on its technology platform while maintaining adequate liquidity to fund operations.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+76.4%
$55K→$97K

Interest expense surged 76.4% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
-52.8%
$13.7M→$6.5M

Capex reduced 52.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

R&D Expense
P&L
+51.2%
$314.4M→$475.3M

R&D investment increased 51.2% — signals commitment to future product development, though near-term margin impact.

Total Debt
Balance Sheet
-49.7%
$19.0M→$9.6M

Debt reduced 49.7% — deleveraging strengthens balance sheet and reduces financial risk.

Net Income
P&L
-39.1%
-$463.7M→-$644.8M

Net income declined 39.1% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-35.3%
-$479.0M→-$648.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Revenue
P&L
+26.9%
$58.8M→$74.7M

Revenue growing 26.9% — solid top-line momentum, watch margins for quality of growth.

Cash & Equivalents
Balance Sheet
+25.1%
$594.4M→$743.3M

Cash grew 25.1% — improving liquidity position supports investment and shareholder returns.

Current Liabilities
Balance Sheet
-21.2%
$187.5M→$147.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-17%
$413.8M→$343.3M

Liabilities reduced 17% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-28
ADDED
As of January 31, 2026, there were 521,950,663 and 5,447,334 shares of the registrant s Class A and B common stock, respectively, par value $0.00001 per share outstanding, respectively.
A Letter from Our CEO Dear Shareholders, 2025 marked an important inflection point for Recursion the year our AI-native foundation began translating from theoretical advantage into clinical reality.
We moved from vision and promise to demonstrating tangible clinical evidence powered by our end-to-end AI-native operating system for creating medicines, and we did so with growing confidence, discipline, and momentum.
As I reflect on the year behind us and look ahead to 2026 and beyond, I believe Recursion is entering one of its most consequential chapters yet.
The foundational question is no longer whether AI can play a role in drug discovery and development.
We have demonstrated that it can and we believe the next decade will be defined by how deeply AI is embedded into the fabric of new medicines itself.
The more important question now is: what value does it create, and how does that value show up in the lives of patients?
Quality medicines are the standard by which AI in medicine will ultimately be judged.
That value will not come from AI layered onto the margins of R D, but from seamlessly integrating AI into the drug discovery and development process itself improving probability of success, compressing timelines, and deploying capital more efficiently.
We are positioning Recursion not only to meet that standard, but to define it.
REMOVED
As of January 31, 2025, there were 395,072,094 and 6,918,575 shares of the registrant s Class A and B common stock, respectively, par value $0.00001 per share outstanding, respectively.
A Letter from Our Co-Founder and CEO Dear Shareholders, As we step into 2025, I want to take a moment to reflect on where Recursion stands today and where we are headed.
The future of our company and of the broader pharmaceutical industry depends on our ability to maintain an unwavering commitment to a bold, audacious vision.
This is even more true in challenging times where funding, both for biotech companies and the early research that drives our industry forward, are facing headwinds.
At Recursion, we are driven by a singular mission: to decode biology to radically improve lives.
We are harnessing the power of cutting-edge technology, vast datasets, and foundation models to transform the way drugs are discovered and developed.
And while we ve adjusted our sails to the winds of our industry, capital markets and more, we ve never altered our destination.
We won t settle for anything less than achieving this mission, and I m proud to lead a company where we take that approach, from our employees, to our leadership, and to our Board of Directors.
Our boldness in the face of stormy weather is one of the things that makes us the leader in TechBio.
Largest merger or acquisition IN THE TECHBIO SPACE TO DATE WITH EXSCIENTIA Recursion s commitment to revolutionizing drug development took a major leap forward last year with the announcement of the largest merger or acquisition in the TechBio space to date our combination with Exscientia.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →